JP2022538911A5 - - Google Patents

Info

Publication number
JP2022538911A5
JP2022538911A5 JP2022500075A JP2022500075A JP2022538911A5 JP 2022538911 A5 JP2022538911 A5 JP 2022538911A5 JP 2022500075 A JP2022500075 A JP 2022500075A JP 2022500075 A JP2022500075 A JP 2022500075A JP 2022538911 A5 JP2022538911 A5 JP 2022538911A5
Authority
JP
Japan
Prior art keywords
sustained
release composition
composition according
less
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022500075A
Other languages
English (en)
Japanese (ja)
Other versions
JP7662204B2 (ja
JP2022538911A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040757 external-priority patent/WO2021003433A1/en
Publication of JP2022538911A publication Critical patent/JP2022538911A/ja
Publication of JP2022538911A5 publication Critical patent/JP2022538911A5/ja
Application granted granted Critical
Publication of JP7662204B2 publication Critical patent/JP7662204B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500075A 2019-07-03 2020-07-02 エンドキシフェンの徐放性組成物 Active JP7662204B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962870656P 2019-07-03 2019-07-03
US62/870,656 2019-07-03
US202062989342P 2020-03-13 2020-03-13
US62/989,342 2020-03-13
US202063021549P 2020-05-07 2020-05-07
US63/021,549 2020-05-07
PCT/US2020/040757 WO2021003433A1 (en) 2019-07-03 2020-07-02 Sustained release compositions of endoxifen

Publications (3)

Publication Number Publication Date
JP2022538911A JP2022538911A (ja) 2022-09-06
JP2022538911A5 true JP2022538911A5 (https=) 2023-07-11
JP7662204B2 JP7662204B2 (ja) 2025-04-15

Family

ID=74100751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500075A Active JP7662204B2 (ja) 2019-07-03 2020-07-02 エンドキシフェンの徐放性組成物

Country Status (10)

Country Link
US (2) US12201591B2 (https=)
EP (1) EP3993782A4 (https=)
JP (1) JP7662204B2 (https=)
KR (1) KR20220042352A (https=)
CN (1) CN114302717A (https=)
AU (2) AU2020300624B2 (https=)
CA (1) CA3145867A1 (https=)
IL (1) IL289557A (https=)
MX (1) MX2022000203A (https=)
WO (1) WO2021003433A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CA3185993A1 (en) * 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
EP4304574A4 (en) * 2021-03-11 2024-11-20 Atossa Therapeutics, Inc. ENDOXIFEN FOR THE TREATMENT OF OVARIAN CANCER
MX2024005220A (es) * 2021-10-28 2024-05-16 Atossa Therapeutics Inc Endoxifeno para el tratamiento del cancer.
AU2023260712A1 (en) * 2022-04-26 2024-11-14 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use
WO2024253935A1 (en) 2023-06-05 2024-12-12 Nanopharmaceutics, Inc. Compositions and methods for oral delivery of sustained release crystalline prx-3140
TW202541789A (zh) * 2023-12-18 2025-11-01 美商阿托薩醫療公司 (z)-因多昔芬(endoxifen)之口服調配物及其使用方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
JP2005512997A (ja) 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠
WO2004054557A2 (en) 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
JP4684655B2 (ja) 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル 4−ヒドロキシタモキシフェンによる乳房密度低下
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
EP1663142A2 (en) 2003-06-23 2006-06-07 MacroChem Corporation Compositons and methods for topical administration
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005070951A1 (en) 2004-01-16 2005-08-04 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
US8436029B2 (en) 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
JP2008537942A (ja) 2005-03-31 2008-10-02 マイトジェン, インコーポレイテッド 心疾患のための処置
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2608904A1 (en) 2005-07-06 2007-09-07 Sicor Inc. Improved process for the preparation of letrozole
CN102225046A (zh) 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
RU2008118363A (ru) 2005-10-12 2009-11-20 Кова Ко., Лтд. (Jp) Ионтофоретический препарат для лечения рака молочной железы и/или мастита
US20090208944A1 (en) 2005-12-09 2009-08-20 Goetz Matthew P Assessing outcomes for breast cancer patients treated with tamoxifen
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
EP2029557A1 (en) 2006-06-05 2009-03-04 Cadila Healthcare Ltd. A process for preparing pure anastrozole
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
DK2101731T3 (en) 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc ENDOXIFEN FOR USING CANCER TREATMENT
WO2008066783A2 (en) * 2006-11-27 2008-06-05 Ariad Pharmaceuticals, Inc. Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
MX337408B (es) 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2009032699A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
WO2009069140A1 (en) 2007-11-28 2009-06-04 Dabur Pharma Limited An improved process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US20100069781A1 (en) 2008-04-15 2010-03-18 Johansen Jerald A Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン2,3−ジオキシゲナーゼの阻害剤としての1,2,5−オキサジアゾール
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ,インク. 薬物送達医療デバイス
CN102227441A (zh) 2008-10-15 2011-10-26 斯索恩有限公司 制备氟维司群的方法和中间体
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
SI3202420T1 (sl) 2008-12-11 2020-08-31 Besins Healthcare Luxembourg Sarl Transdermalni farmacevtski sestavki, ki obsegajo serm
CN103896786B (zh) 2009-05-21 2015-11-25 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
IN2012DN00570A (https=) * 2009-07-14 2015-06-12 Polypid Ltd
US20120149761A1 (en) 2009-08-27 2012-06-14 Atossa Genetics, Inc. Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
WO2012125445A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) * 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
WO2013033430A1 (en) 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
US9353132B2 (en) 2012-03-05 2016-05-31 Xavier University Of Louisiana Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
WO2014060640A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
KR20150087400A (ko) 2012-11-20 2015-07-29 버텍스 파마슈티칼스 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
CN113684185A (zh) 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2014141292A2 (en) 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
KR20160061911A (ko) * 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
TW201536278A (zh) 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
US10174381B2 (en) 2013-10-18 2019-01-08 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015106094A1 (en) 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
MX2016011567A (es) 2014-03-11 2016-12-07 Repros Therapeutics Inc Sintesis de clomifeno usando un solvente unico.
CN107076747B (zh) 2014-06-04 2021-02-02 阿托萨治疗学公司 分子乳房摄影术
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团(天津)股份有限公司 托瑞米芬的合成方法
AU2016247674A1 (en) 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
WO2016187122A1 (en) 2015-05-15 2016-11-24 University Of Iowa Research Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
CA2992282A1 (en) 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
EP3365322B1 (en) 2015-10-22 2021-05-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity
DE102015222031A1 (de) 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) * 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
MX2020002684A (es) 2017-09-11 2020-09-25 Atossa Therapeutics Inc Composiciones topicas.
AU2018329182A1 (en) 2017-09-11 2020-03-19 Atossa Therapeutics, Inc. Topical compositions and methods for treatment
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物

Similar Documents

Publication Publication Date Title
JP2022538911A5 (https=)
US20120064133A1 (en) Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations
NO334233B1 (no) Farmasøytisk sammensetning omfattende milnacipran for behandling av irritabel tarmsyndrom
CN102639117A (zh) 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物
AU2012349771A1 (en) Methods for treating cardiovascular disorder
AU2026200417A1 (en) Sustained release compositions of endoxifen
JP2018087217A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用の方法
KR20210117300A (ko) 포스포디에스테라제 억제제를 함유하는 변형 방출 정제 제형
JP2018024693A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用方法
CA3103477A1 (en) Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
JP2018127482A (ja) 夜尿症のための医薬製剤およびその使用の方法
JP4970452B2 (ja) メトホルミン徐放性錠剤およびその製造方法
US20220211650A1 (en) Sustained release formulations
US20250281414A1 (en) High dose endoxifen formulations and methods of use
WO2017093444A1 (en) Compositions for oral administration in the treatment of inflammatory bowel disease
AU2022378576A1 (en) Endoxifen for treatment of cancers
WO2022192488A1 (en) Endoxifen for treatment of ovarian cancer
CN106999468A (zh) 改善cpt‑11在癌症治疗中的口服利用率同时降低cpt‑11所致的肠胃道毒性的方法和配方
WO2011075799A2 (en) Oral antidepressant formulation
US20190374474A1 (en) Pharmaceutical compositions and methods for weight loss
JP2010509293A5 (https=)
RU2018118603A (ru) Фармацевтические композиции диметилфумарата
KR20250151351A (ko) 변형-방출형 알기네이트-기반 조성물
WO2023278300A1 (en) Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof
HK1174274A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine